ATCC Licenses CRISPR/Cas9 Technology from the Broad Institute – Meets untapped needs with release of new isogenic cell line

ATCC, the premier global biological materials resource and standards organization, announces today that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard. ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.